We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register to chat with like-minded investors on our interactive forums.
| Name | Symbol | Market | Type |
|---|---|---|---|
| AstraZeneca PLC | NYSE:AZN | NYSE | Depository Receipt |
| Price Change | % Change | Price | High Price | Low Price | Open Price | Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|
| 0.00 | 0.00% | 54.17 | 0 | 01:00:00 |
From May 2019 to May 2024
By Olga Cotaga
LONDON--AstraZeneca PLC (AZN.LN) and Sanofi SA (SNY) are teaming up to work on a vaccine that prevents lower respiratory tract illness in a new multimillion-euro joint venture.
The U.K. pharmaceutical company said on Friday that it would develop and sell an antibody for a vaccine to innoculate patients against the respiratory syncytial virus to its French counterpart's vaccines division.
Sanofi would make an up-front payment of 120 million euros ($127.3 million) and then pay AstraZeneca up to EUR495 million depending on whether certain production and sales targets are met, the U.K. company said.
AstraZeneca is to handle the manufacturing of the vaccine while Sanofi will sell the product, with the companies splitting the costs and profits equally, AstraZeneca said.
-Write to Olga Cotaga at olga.cotaga@wsj.com, Twitter @OlgaCotaga
(END) Dow Jones Newswires
March 03, 2017 02:44 ET (07:44 GMT)
Copyright (c) 2017 Dow Jones & Company, Inc.
1 Year AstraZeneca Chart |
1 Month AstraZeneca Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
